Chromadex Corp (CDXC) CEO Frank L. Jaksch, Jr. Sells 58,400 Shares of Stock

Chromadex Corp (NASDAQ:CDXC) CEO Frank L. Jaksch, Jr. sold 58,400 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $6.19, for a total value of $361,496.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Chromadex Corp (CDXC) opened at $6.10 on Wednesday. Chromadex Corp has a one year low of $2.26 and a one year high of $7.24. The company has a quick ratio of 4.12, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $324.10, a price-to-earnings ratio of -43.57 and a beta of 1.38.

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its stake in shares of Chromadex by 870.6% in the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock valued at $698,000 after buying an additional 163,817 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Chromadex in the second quarter valued at $168,000. Thompson Davis & CO. Inc. acquired a new stake in shares of Chromadex in the third quarter valued at $128,000. Finally, Granite Investment Partners LLC grew its stake in shares of Chromadex by 5.7% in the third quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock valued at $1,076,000 after buying an additional 13,599 shares in the last quarter. 6.08% of the stock is owned by institutional investors and hedge funds.

CDXC has been the subject of several recent analyst reports. BidaskClub cut Chromadex from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Ladenburg Thalmann Financial Services started coverage on Chromadex in a research note on Monday, September 25th. They set a “buy” rating and a $7.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Chromadex in a research note on Monday, October 2nd. ValuEngine raised Chromadex from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Finally, Zacks Investment Research raised Chromadex from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Tuesday, November 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $7.13.

WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/27/chromadex-corp-cdxc-ceo-frank-l-jaksch-jr-sells-58400-shares-of-stock.html.

About Chromadex

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Insider Buying and Selling by Quarter for Chromadex (NASDAQ:CDXC)

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit